Open AccessPattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
Author(s) -
Deepika Kalo,
Surya Kant,
Kirti Srivastava,
Ajay Sharma
Publication year - 2015
Publication title -
lung india
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 25
eISSN - 0974-598X
pISSN - 0970-2113
DOI - 10.4103/0970-2113.159561
Subject(s) - ethambutol , medicine , rifampicin , isoniazid , streptomycin , mycobacterium tuberculosis , tuberculosis , drug resistance , drug , virology , antibiotics , microbiology and biotechnology , pharmacology , pathology , biology
Mycobacterium tuberculosis (MTB), the human pathogen causes Tuberculosis (TB). It is a highly infectious and globally pandemic disease. The severity increases when the MTB becomes resistant to antituberculosis drugs. India is reported to be in the second place, with the highest number of drug-resistant TB cases. The treatment of drug-resistant TB is even more complicated.